Systems and methods for treatment of hearing using dihexa
US-2024424050-A1 · Dec 26, 2024 · US
Method of attenuating reactions to skin irritants
US10226476B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10226476-B2 |
| Application number | US-201514802893-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 17, 2015 |
| Priority date | Mar 26, 2001 |
| Publication date | Mar 12, 2019 |
| Grant date | Mar 12, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to a method of inhibiting CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Compositions of the invention are useful for the attenuation of CD1d-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration.
First claim
Opening claim text (preview).
What is claimed is: 1. A composition formulated for topical administration comprising: (a) an agent that attenuates CD1d-restricted NK T cell responses, wherein 1) the agent is a phospholipid conjugated to polyethylene glycol (PEG) that binds CD1d and i) inhibits activation of CD1d-restricted NK T cells or ii) blocks CD1d-specific receptors, 2) the phospholipid is 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine (DPPE), and 3) the DPPE is present in an amount greater than 2.5% weight per volume; and (b) a carrier for topical administration, wherein the carrier is a vegetable oil. 2. The composition of claim 1 , wherein the agent is present in an amount between 2.5% weight per volume and 10.0% weight per volume. 3. The composition of claim 1 , wherein the agent is 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N-[Poly (ethylene glycol) 2000] (DPPE-PEG).
Assignees
Inventors
Classifications
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Preparations for care of the skin · CPC title
Medicinal preparations containing organic active ingredients · CPC title
Sphingolipids, e.g. ceramides, cerebrosides, gangliosides · CPC title
Polymers containing oxygen · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10226476B2 cover?
- The present invention is directed to a method of inhibiting CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Compositions of the invention are useful for the attenuation of CD1d-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to atte…
- Who is the assignee on this patent?
- Dana Farber Cancer Inst Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/685. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).